Audiovisual stimulus during urodynamics to provoke detrusor overactivity: A randomized trial

ConclusionsAddition of AV intervention during UDE did not increase the finding of detrusor contractions. The relationship between OAB triggers, urge incontinence, and urodynamic findings remains unclear.
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Children with daytime urinary incontinence secondary to idiopathic overactive bladder (IOAB) commonly present to paediatric urologists following failure of standard urotherapy and/or first-line anticholinergics. Off-label oral medications and intravesical botulinum toxin A (BtA) are being increasingly used for treatment-refractory IOAB, despite the paucity of high-quality evidence and guidelines. Knowledge of contemporary paediatric urologists' practice allows specialists to keep up-to-date with current trends in the management of IOAB in children.
Source: Journal of Pediatric Urology - Category: Urology & Nephrology Authors: Source Type: research
Publication date: Available online 18 October 2019Source: European UrologyAuthor(s): Christopher R. Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers, Emad SiddiquiAbstractBackgroundMirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms.ObjectiveTo summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms.Design, setting, and participantsPooled data analysed from 10 phase 2–4, double-blind, 12-wk mirabegron monotherapy studies in adults with OAB who h...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Elbaset MA, Taha DE, El-Hefnawy AS, Zahran MH, Shokeir AA Abstract PURPOSE: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. METHODS: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control grou...
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
Publication date: November–December 2019Source: Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, SupplementAuthor(s): L Zhu, Y ZhangStudy ObjectiveTo evaluate the long-term safety and effectiveness of inside–out transobturator tape (tension-free vaginal tape-obturator, TVT-O) for the treatment of stress urinary incontinence (SUI).DesignA prospective cohort study. The duration of follow-up was 12years.SettingCenter of obstetrics and gynecology in a tertiary-care hospital.Patients or ParticipantsBetween August 2004 and August 2006, 87 consecutive patients with SUI who underwent TVT-O were enrolled in...
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
Medtronic has filed for FDA approval for its InterStim Micro neurostimulator and the accompanying InterStim SureScan MRI leads. The rechargeable device delivers sacral neuromodulation therapy to treat conditions such as overactive bladder, fecal inco...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Radiology Rehab Source Type: blogs
Conditions:   Overactive Bladder;   Urinary Incontinence Interventions:   Device: Microcurrents;   Device: Placebo Microcurrents Sponsor:   University of Las Palmas de Gran Canaria Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study investigated the effects of a low ‐frequency home‐based incontinence therapy device on quality of life (QoL) and urinary symptoms in women with urinary incontinence. From May 2017 to February 2018, 34 patients, aged ≥ 20 years, with involuntary urine leakage>2 times/week, were recruited to this study. Patients with severe pelvic organ prolapse, pregnancy, virgin status, and psychological problems were excluded. The incontinence home ‐care device treatments were administered in 12‐minute sessions, twice daily for 8 weeks. Simultaneously, hyperthermic conditions of 35°C to 40...
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Medtronic and Axonics are getting ready to square off in sacral neuromodulation, a fast-growing market that was monopolized by Medtronic until a month ago. Last month, Axonics won FDA approval to market its implantable rechargeable sacral neuromodulation (r-SNM) device for the treatment of fecal incontinence, and the company is expected to get FDA approval for overactive bladder and urinary retention any time now. The fecal incontinence approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans without the necessity of having the device explanted. Medtron...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
More News: Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Study | Urology & Nephrology | Women